A second purpose was to examine the role of organizational support on the relationships between self-development propensity and reported self-development activities.
We discuss these findings with reference to the placement of critical sequence residues within the polypeptide chain, the design of polypeptides with lower amyloid formation propensities and the development of aggregation inhibitors as potential therapeutics for protein depositional disorders.
In this study, the sampling of specific parts of parent trees to obtain the different PMs suggests that stem units of each PM had similar physiological states and propensities for root initiation and development.
Model development was broken into two phases: propensity model development and mortality model development.
In the present study, the population of patients is large enough to allow for robust adjustments for comorbidities, extensive subset analysis, and development of propensity scores.
Standard methods for propensity score development were used and a detailed description of these methods is provided in Additional file 1.
Additional details and discussion concerning propensity score development can be viewed in Additional data file 1. Variables used as candidates in the modeling process were clinically relevant baseline variables for which relatively few data values were missing and were strong univariate predictors of the response variable.
Additional details and discussion concerning propensity score development can also be viewed in Additional file 2. In the second step of the statistical adjustment process, a set of logistic models were developed to assess the effect of treatment (low-dose corticosteroid use; non-low-dose corticosteroid use) on hospital mortality.
However, previous estimates of anterior MI as an independent risk factor for LV thrombus or stroke have been inconsistent [5] [14], [16] [25], and information on their propensity for development after current standard interventions (e.g. antiplatelet and fibrinolytic therapy) for acute MI is limited [14].
This approach has limited the overall therapeutic effectiveness and applicability of current antivirals due to restricted viral specificity, a propensity for development of drug resistance, and an inability to control deleterious host-mediated inflammation.
